2024-11-22 05:00:00
France has more than 8 million people suffering from obesity. In this context, the arrival on the market of anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you had difficulty losing weight, your options were very limited. These medications are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and emphasize the lack of perspective on their long-term effects.
In this video, we return to the active ingredient of these new drugs, which imitate a digestive hormone naturally produced by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to be eligible for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To find out more about these new treatments and the excitement they are causing in the financial markets, you will find a complete breakdown below.
Read later
“Understand in three minutes”
The explanatory videos that make up the “Understand in three minutes” series are produced by the Vertical Videos department of the Monde. Broadcast primarily on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to put major events into context in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
1732272259
#antiobesity #drugs #Wegogy #Mounjaro #work #Understand #minutes
How can individuals integrate Wegovy and Mounjaro into a comprehensive weight management strategy that includes lifestyle modifications and other therapies?
**Interview Segment: Understanding the New Anti-Obesity Treatments in France**
**Date:** November 22, 2024
**Interviewer:** [Your Name]
**Guest:** Dr. [Guest’s Name], Obesity Specialist and Researcher
—
**Interviewer:** Welcome, Dr. [Guest’s Name]. France currently has over 8 million people living with obesity. With the recent introduction of Wegovy and Mounjaro to the market, this situation seems to be evolving. What are your thoughts on these new medications?
**Dr. [Guest’s Name]:** Thank you for having me. Indeed, the arrival of Wegovy and Mounjaro offers new hope for many individuals struggling with obesity. These medications work by mimicking the activity of glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and glucose metabolism. For patients who have had limited success with traditional weight loss methods, these drugs could provide an effective alternative.
**Interviewer:** While there is excitement about the effectiveness of these treatments, there are also voices of caution among health professionals. Can you elaborate on those concerns?
**Dr. [Guest’s Name]:** Absolutely. While many specialists praise the efficacy of Wegovy and Mounjaro, emphasizing their potential to aid in substantial weight loss, there is legitimate concern regarding their long-term effects. We don’t yet have a comprehensive understanding of how these medications will impact patients over several years. There is a pressing need for ongoing research to evaluate not just the effectiveness, but also the safety and any possible side effects that could arise from prolonged use.
**Interviewer:** How do you see the role of these treatments within a broader weight management strategy?
**Dr. [Guest’s Name]:** It’s crucial to adopt a multidisciplinary approach to obesity management. These medications should not replace lifestyle modifications, such as diet and exercise, which remain fundamental components of weight loss strategies. They can be a part of a comprehensive plan that includes behavioral therapy and, in some cases, bariatric surgery, particularly for individuals with a BMI of 30 or higher, or 27 with associated health issues [[1](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext)].
**Interviewer:** It’s great to hear your insights on this topic, Dr. [Guest’s Name]. As more people in France look for solutions to obesity, what advice would you give to those considering these new medications?
**Dr. [Guest’s Name]:** I advise anyone considering Wegovy or Mounjaro to consult with their healthcare provider to discuss the potential benefits and risks. It’s important to have a clear understanding of how these drugs fit into an overall health plan and to ensure that they are monitored closely while on treatment. Open communication with healthcare professionals is key to navigating these options successfully.
**Interviewer:** Thank you, Dr. [Guest’s Name], for sharing your expertise on this important subject. It seems clear that while there is hope on the horizon for obesity treatment in France, careful consideration and collaboration are essential.
**Dr. [Guest’s Name]:** Thank you for having me. It’s vital that we keep the conversation going about obesity management and patient care.
—
This short interview highlights the landscape of obesity treatment in France, focusing on the arrival of new medications and the shared responsibility of managing obesity through a comprehensive approach.
